To evaluate the synergistic functions of PMIBcr/Abl‐R6, we chose two imatinib‐resistant cell lines, KU‐812 (CML) and SUP‐B15 (ALL), which both bear the Philadelphia chromosome, the wild‐type Tp53 gene and overexpressed MDM2.[26] As shown in Figure 2C,D, PMIBcr/Abl‐R6 showed great killing efficacy in both KU‐812 and SUP‐B15 cells. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.